<DOC>
	<DOCNO>NCT02601469</DOCNO>
	<brief_summary>An open label , safety study assess potential adrenal suppression follow maximal use treatment DSXS administer twice daily 28 day patient moderate severe plaque psoriasis .</brief_summary>
	<brief_title>Study Assess Potential Adrenal Suppression Following Treatment With DSXS Patients With Plaque Psoriasis</brief_title>
	<detailed_description>1 . The objective study evaluate potential DSXS suppress HPA axis function patient moderate severe plaque psoriasis 2 . To evaluate efficacy parameter , pharmacokinetics adverse event ( AE ) profile DSXS</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Patients confirm diagnosis plaque psoriasis , patient 217 year age ≥ 10 % BSA affect patient age 18 year age old ≥ 20 % BSA affect 2 . Investigator Global Assessment ( IGA ) score 3 ( moderate ) 4 ( severe ) baseline overall disease severity . 3 . Results cortisol response test consider normal show evidence abnormal HPA function adrenal response 1 . Patients 2 year age . 2 . Investigator Global Assessment ( IGA ) less 3 ( moderate ) great 4 ( severe ) baseline . 3 . Current diagnosis type psoriasis stable plaque psoriasis ( i.e. , erythrodermic , exfoliative pustular psoriasis ) . 4 . Results cortisol response test show evidence abnormal HPA function adrenal response</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>